Connect to Pharmapack

Transitioning drugs from IV to subcutaneous (SC) delivery brings new requirements and impacts program considerations for combination product development. In this session, we identify trade-offs that pharma weighs to de-risk combination product development programs involving large volume subcutaneous (LVSC...

Advances in auto-injector design now provide the option to use both 1ml and 2.25mL syringes plus employ technology to adapt to varying fill volumes and viscosities all whilst maintaining the same device form. This provides a solution for the formulation changes that take place during drug development, clin...

Our healthcare industry is evolving. The move from IV to SC injection is being driven by lifecycle management, biosimilar adoption, and the hospital to home trend. Molecules are getting more complex, and patients drive the preference for self-administration resulting in the need for more complex combinatio...

This session will give insights on the trends our sector is facing: decarbonization and circular economy. It will also provide an overview on the work done at industry level. And finally, you will be able to learn more on what Saint-Gobain Life Sciences is willing to offer to supply single-use technologies...

As the number of patients managing chronic diseases continues to increase, self-injection solutions play an important role in enabling the shift towards home care. Identification of potential use errors is a critical task during device development to support patient acceptance and usability. The design of ...

Implementing sustainability in pharmaceutical packaging needs a two-way methodology: on the one hand, a scientific, data-driven approach to support today’s industrial solutions; on the other hand, a ground-breaking , never-stopping innovation research to anticipate future evolutions. With this Learning...

Human Factors Engineering (HFE) process participates in the product development for a safe and effective use by the end-user population. HFE data are under agencies' scrutiny as part of the design control of a drug - device combination product. Timely planning can be challenging during combination product ...

Ability to achieve successful injection of drug or biologic depends on many factors including but not limited to needle diameter, drug viscosity, spring force, lubrication, plunger geometry and material properties. One additional challenge to be considered during verification of the drug delivery system i...

Lyophilization (freeze drying) is a proven process for increasing the shelf life of vaccines, biologics and other injectables. But delivering these products requires several use steps that make them challenging to administer, particularly by patients and caregivers in non-clinical settings. To address thes...

OXYCAPT is a multilayer plastic vial that consists of three layers, COP/New Polyester/COP. The product has achieved excellent oxygen & ultraviolet (UV) light barrier, very low extractables, high pH stability, low protein adsorption, high transparency, high break resistance, lightweight, etc. For example, t...

The presentation will focus on pressing over the pain points of Pharma Manufacturing, where we present the ECOSYSTEM of Körber Pharma as a great solution. I plan to address the burning questions - What is an Ecosystem and why is it so important in Pharma Manufacturing? The specific details on exploring ...

New therapeutic treatments or prophylactic vaccines rely on more complicated drug formulations, often based on biologics. These drugs are highly sensitive and might require low temperature storage to keep them stable over shelf life. These extreme cold supply chain processes, something up to -80°C, provide...

In 2022, the final recommendations of the Product Quality Research Institute were published for Parenteral Drug Products. Apart from the wealth of information and considerations on design of extractable & leachable studies for parenteral drug products in general, it also contains valuable information on sp...

The presentation will look in some detail how aging / stability studies are established and address the following • What is aging / stability? • What is purpose of aging / stability testing? • What about relative humidity? • What risks are involved? • How long is the shelf life of your prod...

We at Körber believe the pharmaceutical industry will ultimately dispense of plastic packaging within a few years. Our Rondo Solutions are pioneering when it comes to sustainability. Today pharmaceutical packaging expects to be innovative, compact, safe, and environmentally friendly. That’s because opin...

Rubber compound FM30 is a well know compound offered by all big syringe manufacturers these days. It is a low extractable compound with a high gas permeability and is suitable for producing both a needle shield and a tip cap which are sterilized by ethylene oxide. There is a clear trend to move from the ...

Packaging is an integral part of the design for pharmaceutical products and medical devices. Not only does one need to take into account the look, feel, and protective qualities of the packaging but design must be considered when determining the sterilization technology. Determining the sterilization techn...

• Market needs for a device to deliver high drug loads to lungs. • Introduction to the Orbital device – features and benefits. • Comparative performance of Orbital to other DPI devices. • Different types of molecules and formulations made using different particle engineering technologies, inc...

Connecting medication and medical devices to the internet can enhance product protection, improve patient safety and outcomes, and optimize processes along complex supply chains. NFC-RFID technologies are increasingly used to provide connectivity benefits more securely and efficiently, ensuring that pharma...

In recent years there are several market trends which are influencing the design of drug delivery devices. The shift to patient care outside the traditional healthcare setting, accelerated by the pandemic, has led to an increase in patient self- treatment. This has also resulted in the need for connected d...

Sub-optimal adherence and persistence to treatment continue to be significant challenges for both on-market drugs and investigational products in clinical development. This is especially true for self-administered medications for chronic disease patients, hence driving the need for improved treatment intak...